Optimizing Multiple Myeloma Treatment and Supportive Care: Clinical and Cost Considerations for Managed Care

Presents

Optimizing Multiple Myeloma Treatment and Supportive Care: Clinical and Cost Considerations for Managed Care

Sponsored by North American Center for Continuing Medical Education, LLC

Faculty

William J. Cardarelli, PharmD
Director of Pharmacy
Atrius Health
Harvard Vanguard Medical Associates
Watertown, Massachusetts

Irene M. Ghobrial, MD
Assistant Professor in Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Learning Objectives

After completing this activity, participants should be able to:

• Compare and contrast the safety and efficacy of available treatment options for patients with newly diagnosed and relapsed/refractory multiple myeloma (MM)
• Outline current guideline-directed therapy for MM and related supportive care issues
• Discuss the role of bisphosphonate therapy as an adjunctive in maintaining bone health and as a primary cancer treatment
• Remove barriers to patient-centric, evidence-based access to traditional and newer therapies for MM and related supportive care

Intended Learners

This activity is designed for managed markets physicians and pharmacists, pharmacy directors, medical directors, formulary decision makers, and other managed care professionals.

Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for these enduring materials.

Release Date: January 18, 2012
Expiration Date: January 18, 2013
Estimated time to complete: 1 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 276-000-11-065-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact Assistant Director, Accreditation Services, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535. The Assistant Director, Accreditation Services will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation Services, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Don M. Benson, Jr., MD, PhD, Assistant Professor of Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Planning Committee

The planning committee comprises of Don M. Benson, Jr., MD, PhD, William J. Cardarelli, PharmD, Irene M. Ghobrial, MD; Laura D'Onofrio, Mary Johnson, Mike Kearney, Nick Lombardi, Randy Robbin, John Savage, and Jessica Steuerman, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:
Dr. Benson: Grant/Research support—Conquer Cancer Foundation Career Development Award, Multiple Myeloma Opportunities for Research and Education, Pelotonia IDEA Grant
Dr. Ghobrial: Grant/Research support—Bristol-Myers Squibb Company, Millennium Pharmaceuticals, Inc., Noxxon Pharma AG; Consultant—Celgene Corporation, Millennium Pharmaceuticals, Inc, Novartis Oncology, Noxxon Pharma AG; Scientific advisor—Millennium Pharmaceuticals, Inc., Novartis Oncology, Noxxon Pharma AG
Dr. Cardarelli has disclosed no relevant financial relationships with any commercial interests.

Ms. D'Onofrio, Ms. Johnson, Mr. Kearney, Mr. Robbin, Mr. Savage, and Ms. Steuerman have disclosed no relevant financial relationships with any commercial interests.

Mr. Lombardi: Stock shareholder—Inspire Pharmaceuticals, Inc., ViroPharma, Inc., Vertex Pharmaceuticals

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that the following off-label/unapproved uses of drugs and/or devices are discussed in their presentations:

The investigational use of HDAC inhibitors and mTOR inhibitors in the treatment of MM.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2012 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support

Supported by an educational grant from Celgene Corporation, Millennium Pharmaceuticals, Inc., and Novartis Oncology